Bluebird Bio Announces More Good News for LentiGlobin Gene Therapy – Exciting Results in Sickle Cell Disease

Submitted by CP Staff on June 15, 2018 - 10:02am

Source:

CP Wire

News Tags:

Headline:

snippet:

Early results in one group exceed initial therapeutic target
Patients (small number in Ph I currently) appear to remain stable for up to two years
LentiGlobin is being studied in both sickle cell disease and β-thalassemia
LentiGlobin granted orphan drug status in both sickle cell disease and β-thalassemia

Search form